Featured News
MindImmune Caps Off a $30M Series A Round
December 1, 2025
MindImmune, a University of Rhode Island based company, has just capped a $30M Series A round. Funds will support the company through an IND and then into the clinic.
MindImmune Caps Off a $30M Series A Round
December 1, 2025
MindImmune, a University of Rhode Island based company, has just capped a $30M Series A round. Funds will support the company through an IND and then into the clinic.
MindImmune Therapeutics $30M funding round, 6th tenant set stage for Ocean State Labs opening
December 1, 2025
MINDIMMUNE THERAPEATUICS, one of the first tenants to commit to space in the upcoming Ocean State Labs, pictured above, announced that it has raised $30 million in Series A funding and appointed Isaac Stoner as its new CEO.
MindImmune Therapeutics $30M funding round, 6th tenant set stage for Ocean State Labs opening
December 1, 2025
MINDIMMUNE THERAPEATUICS, one of the first tenants to commit to space in the upcoming Ocean State Labs, pictured above, announced that it has raised $30 million in Series A funding and appointed Isaac Stoner as its new CEO.
The hospitals’ survival polka (PART 2)
December 1, 2025
A new version of musical chairs has begun in Rhode Island, with patients’ debt and health insurance cliffs creating a downward spiral.
The hospitals’ survival polka (PART 2)
December 1, 2025
A new version of musical chairs has begun in Rhode Island, with patients’ debt and health insurance cliffs creating a downward spiral.
Good news: Alzheimer’s disease solution poised to enter clinic in 2026 (PART 1)
December 1, 2025
New CEO at MindImmune Isaac Stoner shares story about what it’s like to push a boulder uphill for decades — then to arrive on verge of success
Good news: Alzheimer’s disease solution poised to enter clinic in 2026 (PART 1)
December 1, 2025
New CEO at MindImmune Isaac Stoner shares story about what it’s like to push a boulder uphill for decades — then to arrive on verge of success
MindImmune Extends Series A to $30M to Advance Inflammation-Focused Alzheimer’s Therapy into the Clinic and Appoints Isaac Stoner as CEO
November 24, 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--MindImmune Therapeutics, a private company developing new treatments targeting the inflammatory drivers of neurodegenerative disease, today announced two major milestones: the closing of a $10.2 million Series A extension, which brings the total Series A capital raised to $30 million and the appointment of Isaac Stoner as Chief Executive Officer.
MindImmune Extends Series A to $30M to Advance Inflammation-Focused Alzheimer’s Therapy into the Clinic and Appoints Isaac Stoner as CEO
November 24, 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--MindImmune Therapeutics, a private company developing new treatments targeting the inflammatory drivers of neurodegenerative disease, today announced two major milestones: the closing of a $10.2 million Series A extension, which brings the total Series A capital raised to $30 million and the appointment of Isaac Stoner as Chief Executive Officer.
Developing Antibodies To Block Neuroinflammation With MindImmune's Stevin Zorn, Ph.D.
October 22, 2025
In this episode of "Better Biopharma," host Tyler Menichiello is joined by MindImmune's president and CEO, Stevin Zorn, Ph.D. They discuss the development of the company's lead candidate, MITI-101, a monoclonal antibody designed to prevent peripheral immune cells from entering the brain and driving neuroinflammation linked to Alzheimer's disease.
Developing Antibodies To Block Neuroinflammation With MindImmune's Stevin Zorn, Ph.D.
October 22, 2025
In this episode of "Better Biopharma," host Tyler Menichiello is joined by MindImmune's president and CEO, Stevin Zorn, Ph.D. They discuss the development of the company's lead candidate, MITI-101, a monoclonal antibody designed to prevent peripheral immune cells from entering the brain and driving neuroinflammation linked to Alzheimer's disease.
A new paradigm for treating autoimmune diseases of the brain (Part 2)
October 6, 2025
The science behind MindImmune’s journey into the clinic with a new drug to treat Alzheimer’s disease (Part 2)
A new paradigm for treating autoimmune diseases of the brain (Part 2)
October 6, 2025
The science behind MindImmune’s journey into the clinic with a new drug to treat Alzheimer’s disease (Part 2)
A scientific breakthrough on treating Alzheimer’s disease (Part 1)
September 29, 2025
MindImmune plans to enter the clinic in 2026 to test a new drug candidate to counteract Alzheimer’s disease — before it reaches the brain
A scientific breakthrough on treating Alzheimer’s disease (Part 1)
September 29, 2025
MindImmune plans to enter the clinic in 2026 to test a new drug candidate to counteract Alzheimer’s disease — before it reaches the brain
Governor McKee, RI Life Science Hub Announce Five Foundational Companies for Ocean State Labs
September 24, 2025
Managed by Portal Innovations, the state’s first life science incubator will officially open during the first quarter of 2026
Governor McKee, RI Life Science Hub Announce Five Foundational Companies for Ocean State Labs
September 24, 2025
Managed by Portal Innovations, the state’s first life science incubator will officially open during the first quarter of 2026
Fab Five: First Ocean State Labs life sciences tenants announced
September 24, 2025
Rhode Island’s first life science incubator set to officially open in first quarter of 2026
Fab Five: First Ocean State Labs life sciences tenants announced
September 24, 2025
Rhode Island’s first life science incubator set to officially open in first quarter of 2026
Wheeler Bio and MindImmune Therapeutics Sign CDMO Partnership Agreement to Support MindImmune's Lead Alzheimer's Prevention Program, MITI-101
September 17, 2025
Wheeler Bio and MindImmune Therapeutics Sign CDMO Partnership Agreement to Support MindImmune's Lead Alzheimer's Prevention Program, MITI-101
September 17, 2025
MindImmune Awarded Grant to Accelerate IND-Enabling Studies through Rhode Island Life Science Hub
June 1, 2025
MindImmune Therapeutics today announced it has been awarded a grant by Rhode Island Life Science Hub to accelerate the company’s preclinical development...
MindImmune Awarded Grant to Accelerate IND-Enabling Studies through Rhode Island Life Science Hub
June 1, 2025
MindImmune Therapeutics today announced it has been awarded a grant by Rhode Island Life Science Hub to accelerate the company’s preclinical development...
MindImmune Appoints Thomas Prod’homme, Ph.D., as Vice President, Preclinical Development
April 17, 2025
Accomplished immunologist brings 15 years of experience in preclinical development, translational biology and drug discovery
MindImmune Appoints Thomas Prod’homme, Ph.D., as Vice President, Preclinical Development
April 17, 2025
Accomplished immunologist brings 15 years of experience in preclinical development, translational biology and drug discovery
MindImmune Therapeutics Announces $12.4 million Series A Financing
June 13, 2022
Investors participating in the round include Dolby Family Ventures, Pfizer Ventures, the Alzheimer’s Drug Discovery Foundation (ADDF), Trend Venture, RightHill Ventures (an affiliate of the Slater Technology Fund) and several private investors.
MindImmune Therapeutics Announces $12.4 million Series A Financing
June 13, 2022
Investors participating in the round include Dolby Family Ventures, Pfizer Ventures, the Alzheimer’s Drug Discovery Foundation (ADDF), Trend Venture, RightHill Ventures (an affiliate of the Slater Technology Fund) and several private investors.
Other News
MindImmune Therapeutics Appoints Brad Margus and Robert Michael Poole, MD FACP, to its Board of Directors
January 3, 2024
Slater Technology Fund
RightHill Ventures Commits $1.5 Million to Slater-Backed Drug Discovery Company
June 21, 2022
Alzheimer’s Drug Discovery Foundation
Measurement of immune cell recruitment as a biomarker of neuroinflammation in Alzheimer’s disease and other diseases of the central nervous system
January 1, 2022